考研英語(yǔ)往年真題閱讀理解題目解析

時(shí)間：2017-10-20 15:14:28 淑賢744由分享

　　你覺得考研英語(yǔ)最難的題型是什么?肯定很多考生都會(huì)覺得是閱讀理解部分。下面就是學(xué)習(xí)啦小編給大家整理的考研英語(yǔ)往年真題閱讀理解題目解析，希望對(duì)你有用!

　　考研英語(yǔ)閱讀原文

　　In 2010. a federal judge shook America's biotech industry to its core. Companies had won patents for isolated DNA for decades——by 2005 some 20% of human genes were patented. But in March 2010 a judge ruled that genes were unpatentable. Executives were violently agitated. The Biotechnology Industry Organization (BIO)，a trade group, assured members that this was just a "preliminary step" in a longer battle.

　　On July 29th they were relieved, at least temporarily. A federal appeals court overturned the prior decision, ruling that Myriad Genetics could indeed hold patents to two genes that help forecast a woman's risk of breast cancer. The chief executive of Myriad, a company in Utah, said the ruling was a blessing to firms and patients alike.

　　But as companies continue their attempts at personalized medicine, the courts will remain rather busy. The Myriad case itself is probably not over. Critics make three main arguments against gene patents: a gene is a product of nature, so it may not be patented; gene patents suppress innovation rather than reward it; and patents' monopolies restrict access to genetic tests such as Myriad's. A growing number seem to agree. Last year a federal task-force urged reform for patents related to genetic tests. In October the Department of Justice filed a brief in the Myriad case, arguing that an isolated DNA molecule "is no less a product of nature... than are cotton fibres that have been separated from cotton seeds." Despite the appeals court's decision, big questions remain unanswered. For example, it is unclear whether the sequencing of a whole genome violates the patents of individual genes within it. The case may yet reach the Supreme Court。

　　As the industry advances, however, other suits may have an even greater impact. Companies are unlikely to file many more patents for human DNA molecules——most are already patented or in the public domain. Firms are now studying how genes interact, looking for correlations that might be used to determine the causes of disease or predict a drug's efficacy. Companies are eager to win patents for "connecting the dots", explains Hans Sauer, a lawyer for the BIO。

　　Their success may be determined by a suit related to this issue, brought by the Mayo Clinic, which the Supreme Court will hear in its next term. The BIO recently held a convention which included sessions to coach lawyers on the shifting landscape for patents. Each meeting was packed。

　　考研英語(yǔ)閱讀翻譯

　　2010年，一個(gè)聯(lián)邦法官對(duì)美國(guó)生物科技行業(yè)產(chǎn)生了巨大影響。各家公司早就獲得了單個(gè)DNA的專利，2005年大約有20%的人類基因被授予專利。但2010年3月，一位法官判決基因是不能授予專利的。執(zhí)行高管們一下燥熱不安。生物科技行業(yè)組織(BIO)是貿(mào)易組織，該組織認(rèn)為這個(gè)判決是長(zhǎng)期斗爭(zhēng)的一個(gè)前奏。

　　7月29日，他們放松了一下，至少暫時(shí)放松了一會(huì)兒。聯(lián)邦上訴法院推翻了前面的判決，認(rèn)為Myriad Genetics的確可以持有的兩個(gè)幫助預(yù)測(cè)女性乳腺癌的基因?qū)＠?。位于猶他州的Myriad首席執(zhí)行官說，這個(gè)判決對(duì)于公司和患者都是一種賜福。

　　但是，正當(dāng)公司繼續(xù)試圖個(gè)性化醫(yī)療的時(shí)候，法院將繼續(xù)忙于此事。Myriad案本身可能不會(huì)結(jié)束。批評(píng)人士有三個(gè)理由反對(duì)基因?qū)＠夯蚴亲匀坏漠a(chǎn)物，所以不可以給予專利;基因?qū)＠粫?huì)鼓勵(lì)創(chuàng)新反而會(huì)打壓創(chuàng)新;基因壟斷企業(yè)比如Myriad會(huì)限制其它公司進(jìn)行基因測(cè)試。越來越多的人似乎同意這種說法。去年，聯(lián)邦特派組敦促基因檢測(cè)專利改革。十月，司法部在Myriad案中發(fā)表聲明，單個(gè)DNA分子和從棉籽上分離出來的棉纖維一樣，都是自然的產(chǎn)物。盡管上訴法院作出這樣的判決，但是重要的問題仍然沒有得到回答。比如說，基因組序列是否違背了其中單個(gè)基因?qū)＠詿o(wú)定論，這個(gè)問題可能要到最高法院裁決。

　　但是，隨著該行業(yè)的發(fā)展，其它的案例可能會(huì)有更大的影響力。公司不大可能申請(qǐng)到更多的人類DNA專利——有些已經(jīng)被其它公司申請(qǐng)或者處于共同申請(qǐng)的領(lǐng)域。公司正在研究基因是如何相互作用的，基因的相關(guān)性可以用來判斷疾病的起因或者預(yù)測(cè)藥物的功效。BIO的律師Hans Sauer解釋道，公司渴望獲得專利來以便歸納推理得出結(jié)論。

　　他們是否成功可能要由Mayo Clinic帶來的這個(gè)案件的訴訟情況決定。最高法院將在下一輪審理此案。生物科技行業(yè)組織(BIO)最近開會(huì)討論聘用律師來處理?yè)u擺不定的專利案。每個(gè)會(huì)議都人滿為患。